No­var­tis in hot wa­ter again over al­leged kick­backs, re­veal­ing new DoJ probe re­lat­ed to En­tresto

No­var­tis’ En­tresto has proven a block­buster drug since its ap­proval in 2015, net­ting $924 mil­lion in sales this past quar­ter alone, rep­re­sent­ing a 46% gain from last year’s pe­ri­od. But the US gov­ern­ment is call­ing the com­pa­ny’s sales prac­tices in­to ques­tion, de­mand­ing in­fo dat­ing back years in a new­ly re­vealed probe.

The De­part­ment of Jus­tice is seek­ing doc­u­ments as far back as 2016 re­lat­ed to the mar­ket­ing, pric­ing and pay­ments to doc­tors for En­tresto, No­var­tis re­vealed in its third quar­ter reg­u­la­to­ry fil­ing. Per the bio­phar­ma’s ac­count, DoJ ini­ti­at­ed the probe — known for­mal­ly as a Civ­il In­ves­tiga­tive De­mand — this past Sep­tem­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER